quinta-feira, 12 de novembro de 2026
PesquisarExplore
Via News Knowledge File

UBS Group AG

organization80% conf.·synced Aug 13, 2026

Financial services firm providing equity research

46
sourced metrics
601
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Shares Held
533824shares
Total Loss Absorbing Capacity
187000000000CHF
Analyst Price Target
56USD
Ubs Ag Standalone Cet1 Ratio
13.3percent
⚠ sources conflictsource
Buyback Minimum Next Three Months
1USD
Buyback Program Size
3USD
Cet1 Capital Ratio
14.4percent
Cet1 Leverage Ratio
4.4percent
Cost Of Risk Annualized
9basis_points
Cost Savings
700000000CHF
Credit Impaired Exposures
90basis_points
Cumulative Cost Saves
10700000000CHF
Eps
0.37CHF
Integration Expenses
1100000000CHF
Liquidity Coverage Ratio
183percent
Net Stable Funding Ratio
116percent
Operating Expenses Growth
1percent
Pre Tax Profit Underlying
2900000000CHF

Stated objectives

S&P 500 to reach 7,500 by end of 2026

source
target: 7500 by 2026-12-31 00:00:00stated

S&P 500 to reach 7,500 by end of 2026

source
target: 7500 by 2026-12-31 00:00:00stated

UBS predicts gold price will reach $6,200 per ounce

source
target: $6,200 per ounce by 2026-12-31 00:00:00stated

Gold price target of $6,200 for end of 2026

source
target: 6200 by 2026-12-31 00:00:00stated

Gold price forecast

source
target: 6200 USD per ounce by 2026-12-31 00:00:00stated

Increase gross cost savings to CHF 13.5 billion from Credit Suisse integration

source
target: 13500000000 CHF stated

Maintain CET1 capital ratio around 14%

source
target: 14 percent stated

Maintain CET1 leverage ratio above 4%

source
target: above 4 percent stated

Repurchase $3 billion of shares in 2026 with potential for more

source
target: 3000000000 USD minimum by 2026-01-01 00:00:00stated

Achieve underlying return on CET1 capital of approximately 13% for full-year 2026

source
target: 13 percent by 2026-01-01 00:00:00stated

Relationship graph · 601 connections

Covered by
274
Employs
195
rates
54
subsidiary of
17
Competes with
8
Invested in
7
board member of
6
regulates
5

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com